Blockade of Tau Hyperphosphorylation and Aβ1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Neuropsychopharmacology

• Publication date

  2013-03-14

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/npp.2013.70PMID 23493042PMCID PMC3717544
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The γ-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Aβ1-42 seeding and short-term memory deficits in the Aβ25-35 mouse model of Alzheimer's disease.

  2013cited by this paper
• Anti-amnesic effect of neurosteroid PREGS in Aβ25-35-injected mice through σ1 receptor- and α7nAChR-mediated neuroprotection.

  2012cited by this paper
• Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer’s disease

  2012influential reference
• The phosphodiesterase-4 inhibitor rolipram reverses Aβ-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats.

  2012cited by this paper
• Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease.

  2012cited by this paper
• Roles of glycogen synthase kinase 3 in Alzheimer's disease.

  2012cited by this paper
• Synaptic Stimulation of mTOR Is Mediated by Wnt Signaling and Regulation of Glycogen Synthetase Kinase-3

  2011cited by this paper
• A novel glycogen synthase kinase‐3 inhibitor 2‐methyl‐5‐(3‐{4‐[(S )‐methylsulfinyl]phenyl}‐1‐benzofuran‐5‐yl)‐1,3,4‐oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer’s disease

  2011cited by this paper
• Xanthoceraside attenuates amyloid β peptide25–35-induced learning and memory impairments in mice

  2011cited by this paper
• Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative

  2011influential reference
• Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid β fragment in rats.

  2011influential reference
• GSK3 and Alzheimer’s Disease: Facts and Fiction…

  2011cited by this paper
• Cognitive dysfunctions induced by a cholinergic blockade and Aβ 25-35 peptide are attenuated by salvianolic acid B.

  2011cited by this paper
• ERK1-independent α-secretase cut of β-amyloid precursor protein via M1 muscarinic receptors and PKCα/ε.

  2011cited by this paper
• Sigma-1 Receptors Regulate Bcl-2 Expression by Reactive Oxygen Species-Dependent Transcriptional Regulation of Nuclear Factor κB

  2010cited by this paper
• Dysregulation of the mTOR Pathway Mediates Impairment of Synaptic Plasticity in a Mouse Model of Alzheimer's Disease

  2010cited by this paper
• DHEA prevents Aβ25-35-impaired survival of newborn neurons in the dentate gyrus through a modulation of PI3K-Akt-mTOR signaling.

  2010cited by this paper
• Imipramine, in Part through Tumor Necrosis Factor α Inhibition, Prevents Cognitive Decline and β-Amyloid Accumulation in a Mouse Model of Alzheimer's Disease

  2010cited by this paper
• Anesthetic-Induced Neurodegeneration Mediated via Inositol 1,4,5-Trisphosphate Receptors

  2010cited by this paper
• Effects of trans-2,4-dimethoxystibene against the neurotoxicity induced by Abeta(25-35) both in vitro and in vivo.

  2010cited by this paper
• Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473-phosphorylation of Akt-1 in PC12 cells.

  2010cited by this paper
• Nicotine exacerbates tau phosphorylation and cognitive impairment induced by amyloid-beta 25-35 in rats.

  2010cited by this paper
• GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals.

  2009cited by this paper
• Antiamnesic and Neuroprotective Effects of the Aminotetrahydrofuran Derivative ANAVEX1-41 Against Amyloid β25–35-Induced Toxicity in Mice

  2009cited by this paper
• Oxidative stress up‐regulates presenilin 1 in lipid rafts in neuronal cells

  2009cited by this paper
• Calcineurin dephosphorylates glycogen synthase kinase‐3 beta at serine‐9 in neuroblast‐derived cells

  2009influential reference
• The GSK3 hypothesis of Alzheimer's disease

  2008cited by this paper
• Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease-modifying agents for Alzheimer’s disease

  2008cited by this paper
• Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain

  2008cited by this paper
• Involvement of the sigma1 (σ1) receptor in the anti‐amnesic, but not antidepressant‐like, effects of the aminotetrahydrofuran derivative ANAVEX1‐41

  2007cited by this paper
• LTP inhibits LTD in the hippocampus via regulation of GSK3beta.

  2007influential reference
• A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35.

  2007cited by this paper
• A neural cell adhesion molecule–derived peptide reduces neuropathological signs and cognitive impairment induced by Aβ25-35

  2007influential reference
• Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival.

  2007cited by this paper
• Chronic Antidepressants Potentiate via Sigma-1 Receptors the Brain-derived Neurotrophic Factor-induced Signaling for Glutamate Release*

  2006cited by this paper
• M1 receptors play a central role in modulating AD-like pathology in transgenic mice.

  2006influential reference
• The anti‐amnesic and neuroprotective effects of donepezil against amyloid β25‐35 peptide‐induced toxicity in mice involve an interaction with the σ1 receptor

  2006cited by this paper
• The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways.

  2006cited by this paper
• Glycogen synthase kinase-3--an overview of an over-achieving protein kinase.

  2006cited by this paper
• Role of GSK‐3β activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene

  2005cited by this paper
• Aβ25–35 Alters AKT Activity, Resulting in Bad Translocation and Mitochondrial Dysfunction in Cerebrovascular Endothelial Cells

  2005cited by this paper
• Pin1 promotes production of Alzheimer's amyloid beta from beta-cleaved amyloid precursor protein.

  2005cited by this paper
• Gene expression profile of amyloid beta protein-injected mouse model for Alzheimer disease

  2005cited by this paper
• Tau phosphorylation: physiological and pathological consequences.

  2005cited by this paper
• Studies of the Effects of Central Administration of β-Amyloid Peptide (25–35): Pathomorphological Changes in the Hippocampus and Impairment of Spatial Memory

  2005cited by this paper
• Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event.

  2004cited by this paper
• Pathways towards and away from Alzheimer's disease

  2004cited by this paper
• Glycogen synthase kinase 3: a drug target for CNS therapies

  2004cited by this paper
• Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases

  2004cited by this paper
• Amyloid-β(25–35)-induced memory impairments correlate with cell loss in rat hippocampus

  2004cited by this paper
• Protein kinase C-dependent potentiation of intracellular calcium influx by sigma1 receptor agonists in rat hippocampal neurons.

  2003cited by this paper
• σ-1 Receptors (σ1 Binding Sites) Form Raft-Like Microdomains and Target Lipid Droplets on the Endoplasmic Reticulum: Roles in Endoplasmic Reticulum Lipid Compartmentalization and Export

  2003cited by this paper
• Single intracerebroventricular administration of amyloid-beta (25-35) peptide induces impairment in short-term rather than long-term memory in rats.

  2003cited by this paper
• Protein Kinase C-Dependent Potentiation of Intracellular Calcium Influx by σ1 Receptor Agonists in Rat Hippocampal Neurons

  2003cited by this paper
• Immunocytochemical evidence that amyloid beta (1-42) impairs endogenous antioxidant systems in vivo.

  2003cited by this paper
• Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export.

  2003cited by this paper
• Overactivation of glycogen synthase kinase‐3 by inhibition of phosphoinositol‐3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory

  2003influential reference
• Mécanisme d'action de la tétrahydro-N, N-diméthyl-5, 5-diphényl-3-furaneméthanamine, un dérivé potentiellement nootrope, antiépileptique et antidépresseur.

  2002influential reference
• [Mechanism of action of tetrahydro-N, N-dimethyl-5, 5-diphenyl-3-furanemethanamine, a putative nootropic, anti-epileptic and antidepressant compound].

  2002influential reference
• Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors.

  2002cited by this paper
• Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Abeta(25-35)-induced abnormal tau protein immunoreactivity in rat brain.

  2002cited by this paper
• [Anticonvulsant and forced swim anti-immobility effects of tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanemethanamine (AE37): common action mechanism?].

  2002cited by this paper
• Spatial learning deficit in transgenic mice that conditionally over‐express GSK‐3β in the brain but do not form tau filaments

  2002cited by this paper
• Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition.

  2001cited by this paper
• Decreased nuclear β‐catenin, tau hyperphosphorylation and neurodegeneration in GSK‐3β conditional transgenic mice

  2001cited by this paper
• Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice.

  2001cited by this paper
• Regulating ankyrin dynamics: Roles of sigma-1 receptors.

  2001cited by this paper
• Memory deficits and increased emotionality induced by β-amyloid (25–35) are correlated with the reduced acetylcholine release and altered phorbol dibutyrate binding in the hippocampus

  2001cited by this paper
• Crystal Structure of Glycogen Synthase Kinase 3β: Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition

  2001cited by this paper
• Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration.

  2000cited by this paper
• Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal.

  2000cited by this paper
• Ca2+ Signaling via ς1-Receptors: Novel Regulatory Mechanism Affecting Intracellular Ca2+Concentration

  2000cited by this paper
• Ca(2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca(2+) concentration.

  2000cited by this paper
• Intracellular sigma1 receptor modulates phospholipase C and protein kinase C activities in the brainstem.

  1999cited by this paper
• Sigma1 (σ1) receptor agonists and neurosteroids attenuate β25–35-amyloid peptide-induced amnesia in mice through a common mechanism

  1998cited by this paper
• Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons.

  1998cited by this paper
• Estrogens stabilize mitochondrial function and protect neural cells against the pro‐apoptotic action of mutant presenilin‐1

  1997cited by this paper
• In vitro aggregation facilities beta-amyloid peptide-(25-35)-induced amnesia in the rat.

  1997cited by this paper
• Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

  1997cited by this paper
• Estrogens stabilize mitochondrial function and protect neural cells against the pro-apoptotic action of mutant presenilin-1.

  1997cited by this paper
• In vitro aggregation facilitates β-amyloid peptide-(25–35)-induced amnesia in the rat

  1997cited by this paper
• Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta.

  1996cited by this paper
• Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction.

  1996cited by this paper
• Exposure of rat hippocampal neurons to amyloid β peptide (25–35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3β

  1996cited by this paper
• Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.

  1994cited by this paper
• Tau protein I is essential for amyloid β-protein iduced neurotoxicity

  1993cited by this paper
• Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity.

  1993cited by this paper
• Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors.

  1992cited by this paper
• Cellular aspects of Alzheimer neurofibrillary pathology.

  1992cited by this paper
• Cellular aspects of Alzheimer neurofibrillary pathology.

  1992cited by this paper
• Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand.

  1991cited by this paper
• THE SIGNIFICANCE OF THE "FOLLAR RAY".

  1923cited by this paper

• Butyrate antagonizes Annexin A2-mediated tauopathy via Annexin A1 reciprocity in Alzheimer's disease.

  2026cites this paper
• A Dual Approach To Combat Alzheimer's Disease through Concomitant hBChE Inhibition and S1R Activation.

  2026cites this paper
• The sigma-1 receptor as a neurohomeostatic decision hub for GABARAP-mediated receptor trafficking and macroautophagy

  2025cites this paper
• Astrocyte Autophagy in Neurodegenerative Diseases: Current Progress in Mechanisms and Therapeutics

  2025cites this paper
• The protective effect of DMT against neurodegeneration.

  2025cites this paper
• SG06, a Chalcone Derivative Targets PI3K/AKT1 Pathway for Neuroprotection and Cognitive Enhancement in an Alzheimer’s Disease-Like Zebrafish Model

  2025cites this paper
• CD22 modulation alleviates amyloid β-induced neuroinflammation

  2025cites this paper
• Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial

  2025cites this paper
• CNEURO-201, an Anti-amyloidogenic Agent and σ1-Receptor Agonist, Improves Cognition in the 3xTg Mouse Model of Alzheimer’s Disease by Multiple Actions in the Pathology

  2025cites this paper
• Targeting neuroinflammation by activation of the sigma-1 receptor (S1R) and inhibition of butyrylcholinesterase (hBChE) leads to highly potent anti-amnesic compounds in an Alzheimer's disease mouse model.

  2025cites this paper
• Endoplasmic reticulum stress and the unfolded protein response: emerging regulators in progression of traumatic brain injury

  2024cites this paper
• Comprehensive review on Alzheimer's disease: From the posttranslational modifications of Tau to corresponding treatments

  2024cites this paper
• Current Update on Promising New Anti-Alzheimer's Drugs in Different Phases of Clinical Development: Where Exactly Are We Lacking?

  2024cites this paper
• Exploring the Benzazoles Derivatives as Pharmacophores for AChE, BACE1, and as Anti-Aβ Aggregation to Find Multitarget Compounds against Alzheimer’s Disease

  2024cites this paper
• Now and future: Strategies for diagnosis, prevention and therapies for Alzheimer's disease.

  2024cites this paper
• Muscarinic Receptors and Alzheimer’s Disease: New Perspectives and Mechanisms

  2024cites this paper
• Amylovis-201 is a new dual-target ligand, acting as an anti-amyloidogenic compound and a potent agonist of the σ1 chaperone protein

  2024cites this paper
• The involvement of SigmaR1K142 degradation mediated by ERAD in neural senescence linked with CdCl2 exposure.

  2024cites this paper
• Optimizing drug-like properties of selective butyrylcholinesterase inhibitors for cognitive improvement: Enhancing aqueous solubility by disrupting molecular plane.

  2024cites this paper
• Recent trends in treatment strategies for Alzheimer's disease and the challenges: A topical advancement.

  2024cites this paper
• Flavonoids as G Protein-coupled Receptors Ligands: New Potential Therapeutic Natural Drugs.

  2023cites this paper
• Convolamine, a tropane alkaloid extracted from Convolvulus plauricalis, is a potent sigma‐1 receptor‐positive modulator with cognitive and neuroprotective properties

  2023cites this paper
• The Sigma Receptors in Alzheimer’s Disease: New Potential Targets for Diagnosis and Therapy

  2023cites this paper
• Targeted to neuronal organelles for CNS drug development.

  2023cites this paper
• Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future

  2023cites this paper
• Therapeutic Potential of Heterocyclic Compounds Targeting Mitochondrial Calcium Homeostasis and Signaling in Alzheimer’s Disease and Parkinson’s Disease

  2023cites this paper
• Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders

  2023cites this paper
• Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimer’s Disease Mouse Model

  2023cites this paper
• Therapies for Tau-associated neurodegenerative disorders: targeting molecules, synapses, and cells

  2023cites this paper
• The pathomimetic oAβ25-35 model of Alzheimer's disease: Potential for screening of new therapeutic agents.

  2023cites this paper
• Sigma-1 Receptor as a Protective Factor for Diabetes-Associated Cognitive Dysfunction via Regulating Astrocytic Endoplasmic Reticulum-Mitochondrion Contact and Endoplasmic Reticulum Stress

  2023cites this paper
• Chaperone-Dependent Mechanisms as a Pharmacological Target for Neuroprotection

  2023cites this paper
• NMDA and AMPA Receptors at Synapses: Novel Targets for Tau and α-Synuclein Proteinopathies

  2022cites this paper
• Novel benzimidazole-based pseudo-irreversible butyrylcholinesterase inhibitors with neuroprotective activity in an Alzheimer's disease mouse model.

  2022cites this paper
• Activation of Sigma-1 Receptor Alleviates ER-Associated Cell Death and Microglia Activation in Traumatically Injured Mice

  2022cites this paper
• Endoplasmic Reticulum-Mitochondria Contacts Modulate Reactive Oxygen Species-Mediated Signaling and Oxidative Stress in Brain Disorders: The Key Role of Sigma-1 Receptor

  2022cites this paper
• Activation of the sigma-1 receptor chaperone alleviates symptoms of Wolfram syndrome in preclinical models

  2022cites this paper
• Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders

  2022cites this paper
• Therapeutic Strategies Targeting Mitochondrial Calcium Signaling: A New Hope for Neurological Diseases?

  2022cites this paper
• Discovery of Potent Cholinesterase Inhibition-Based Multi-Target-Directed Lead Compounds for Synaptoprotection in Alzheimer's Disease.

  2022cites this paper
• Assignment of Absolute Configuration to Enantiomers of Anti-Alzheimer Drug Candidate Blarcamesine

  2022cites this paper
• Joint Computational/Cell-Based Approach for Screening Inhibitors of Tau Oligomerization: A Proof-of-Concept Study

  2022cites this paper
• Multi-Target-Directed Ligands as an Effective Strategy for the Treatment of Alzheimer's Disease.

  2021cites this paper
• Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection.

  2021cites this paper
• Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy

  2021cites this paper
• Mitochondria‐associated endoplasmic reticulum membranes: At the crossroad between familiar and sporadic Alzheimer's disease

  2021cites this paper
• Metabolic disorder in Alzheimer’s disease

  2021cites this paper
• Involvement of the Sigma-1 Receptor in Neuronal Cell Death and Alzheimer's Disease

  2021cites this paper
• Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders

  2021cites this paper
• Mitochondrial Aspects of Neuronal Pathology in Triple-Transgenic Alzheimer’s Disease Mice

  2021cites this paper
• Sigma-1 Receptor: A Potential Therapeutic Target for Traumatic Brain Injury

  2021cites this paper
• Structure–activity relationship, in vitro and in vivo evaluation of novel dienyl sulphonyl fluorides as selective BuChE inhibitors for the treatment of Alzheimer's disease

  2021cites this paper
• Enlargement of early endosomes and traffic jam in basal forebrain cholinergic neurons in Alzheimer's disease.

  2021cites this paper
• Multi-Target Directed Ligands (MTDLs) Binding the σ1 Receptor as Promising Therapeutics: State of the Art and Perspectives

  2021cites this paper
• Selective Pseudo-irreversible Butyrylcholinesterase Inhibitors Transferring Antioxidant Moieties to the Enzyme Show Pronounced Neuroprotective Efficacy In Vitro and In Vivo in an Alzheimer's Disease Mouse Model.

  2021cites this paper
• The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimer’s

  2021cites this paper
• Sigma-1 receptor agonists as potential protective therapies in multiple sclerosis.

  2020cites this paper
• At the Crossing of ER Stress and MAMs: A Key Role of Sigma-1 Receptor?

  2020cites this paper
• Distinct Regulation of σ1 Receptor Multimerization by Its Agonists and Antagonists in Transfected Cells and Rat Liver Membranes

  2020cites this paper
• Inflamation and oxidative stress : The molecular connectivity between insulin resistance, obesity and Alzheimer's disease

  2020influential citation
• Dehydroepiandrosterone (DHEA) and its Sulphate (DHEAS) in Alzheimer's Disease.

  2020cites this paper
• A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2‐73) Phase 2a clinical study

  2020cites this paper
• Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease

  2020cites this paper
• Sterubin: Enantioresolution and Configurational Stability, Enantiomeric Purity in Nature, and Neuroprotective Activity in Vitro and in Vivo

  2020cites this paper
• Alzheimer's Disease Therapeutic Approaches.

  2020cites this paper
• PRE-084 as a tool to uncover potential therapeutic applications for selective sigma-1 receptor activation.

  2020cites this paper
• A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy

  2020cites this paper
• Multi-Target Drug Candidates for Multifactorial Alzheimer’s Disease: AChE and NMDAR as Molecular Targets

  2020cites this paper
• Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer’s Disease

  2020cites this paper
• Sigma ligands as potent inhibitors of Aβ and AβOs in neurons and promising therapeutic agents of Alzheimer's disease.

  2020cites this paper
• Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders

  2020cites this paper
• Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.

  2020cites this paper
• Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain

  2020cites this paper
• Dual-targeting approach on histamine H3 and sigma-1 receptor ligands as promising pharmacological tools in the treatment of CNS-linked disorders.

  2020cites this paper
• Molecular Dysfunctions of Mitochondria-Associated Membranes (MAMs) in Alzheimer’s Disease

  2020cites this paper
• Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease

  2019cites this paper
• Highly Selective Butyrylcholinesterase Inhibitors with Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer's Disease Mouse Model.

  2019cites this paper
• Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways

  2019cites this paper
• Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor.

  2019cites this paper
• Mitochondrial dynamics and transport in Alzheimer's disease.

  2019cites this paper
• 7-O-Esters of taxifolin with pronounced and overadditive effects in neuroprotection, anti-neuroinflammation, and amelioration of short-term memory impairment in vivo

  2019cites this paper
• ANAVEX®2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome.

  2019cites this paper
• Molecular expression of insulin signal transduction components in brain cells in an experimental model of Alzheimer’s disease

  2019cites this paper
• Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases

  2019cites this paper
• Dual-Acting Cholinesterase-Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo.

  2019cites this paper
• AF710B, an M1/sigma‐1 receptor agonist with long‐lasting disease‐modifying properties in a transgenic rat model of Alzheimer's disease

  2018cites this paper
• Amyloid toxicity is enhanced after pharmacological or genetic invalidation of the &sgr;1 receptor

  2018cites this paper
• Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric A (cid:12) 25-35 peptide administration in mice.

  2018cites this paper
• Topographical memory analyzed in mice using the Hamlet test, a novel complex maze

  2018cites this paper
• Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles.

  2018cites this paper
• Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases

  2018cites this paper
• Improvement of BDNF signalling by P42 peptide in Huntington's disease

  2018cites this paper
• The Basal Forebrain Regulates Global Resting-State fMRI Fluctuations.

  2018cites this paper
• Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties.

  2018cites this paper
• Sigma-1 Receptor Agonists Induce Oxidative Stress in Mitochondria and Enhance Complex I Activity in Physiological Condition but Protect Against Pathological Oxidative Stress

  2017cites this paper
• Role of Sigma-1 Receptor in Cocaine Abuse and Neurodegenerative Disease.

  2017cites this paper
• Therapeutics of Neurotransmitters in Alzheimer’s Disease

  2017cites this paper
• Multiple Ligands in Neurodegenerative Diseases

  2017cites this paper
• Sigma 1 Receptor and Ion Channel Dynamics in Cancer.

  2017cites this paper
• Sigma-1 (σ1) Receptor in Memory and Neurodegenerative Diseases.

  2017cites this paper